| 2.49 0.05 (2.05%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.2 | 1-year : | 3.74 |
| Resists | First : | 2.74 | Second : | 3.2 |
| Pivot price | 2.19  |
|||
| Supports | First : | 1.97 | Second : | 1.5 |
| MAs | MA(5) : | 2.38 |
MA(20) : | 2.04 |
| MA(100) : | 3.45  |
MA(250) : | 4.77 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 72 |
D(3) : | 69.3 |
| RSI | RSI(14): 59.6 |
|||
| 52-week | High : | 8.32 | Low : | 1.5 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ CRBU ] has closed below upper band by 28.9%. Bollinger Bands are 3.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.57 - 2.58 | 2.58 - 2.59 |
| Low: | 2.42 - 2.44 | 2.44 - 2.45 |
| Close: | 2.47 - 2.49 | 2.49 - 2.51 |
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
Fri, 26 Jul 2024
Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Share Price Boosted 39% But Its Business Prospects Need A Lift Too - Simply Wall St
Wed, 24 Jul 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Caribou Biosciences, Inc. - CRBU - PR Newswire
Sun, 21 Jul 2024
Entropy Technologies LP Makes New $113,000 Investment in Caribou Biosciences, Inc. (NASDAQ:CRBU) - Defense World
Fri, 19 Jul 2024
Analysts Issue Forecasts for Caribou Biosciences, Inc.’s Q3 2024 Earnings (NASDAQ:CRBU) - Defense World
Tue, 16 Jul 2024
Is Caribou Biosciences (NASDAQ:CRBU) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 90 (M) |
| Held by Insiders | 6.915e+007 (%) |
| Held by Institutions | 10 (%) |
| Shares Short | 11,510 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.273e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 893.8 % |
| Return on Equity (ttm) | -21.8 % |
| Qtrly Rev. Growth | 3.34e+007 % |
| Gross Profit (p.s.) | -13.43 |
| Sales Per Share | -16.27 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -103 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | -0.1 |
| Price to Book value | 0 |
| Price to Sales | -0.16 |
| Price to Cash Flow | 1.49 |
| Dividend | 0 |
| Forward Dividend | 1.025e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|